rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2016-1S-75-79rsp-2257Research ArticleОБЗОРЫИНГИБИТОРЫ ФАКТОРА НЕКРОЗА ОПУХОЛИ Α В ЛЕЧЕНИИ АКСИАЛЬНЫХ СПОНДИЛОАРТРИТОВ, ВКЛЮЧАЯ АНКИЛОЗИРУЮЩИЙ СПОНДИЛИТTUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITISЛапшинаС. А.LapshinaS. A.ДубининаТ. В.DubininaT. V.tatiana-dubinina@mail.ruБадокинВ. В.BadokinV. V.БочковаА. Г.BochkovaA. G.БугроваО. В.BugrovaO. V.ГайдуковаИ. З.GaidukovaI. Z.ГодзенкоА. А.GodzenkoA. A.ДубиковА. А.DubikovA. A.ИвановаО. Н.IvanovaO. N.КоротаеваТ. В.KorotaevaT. V.НесмеяноваО. Б.NesmeyanovaO. B.НикишинаИ. П.NikishinaI. P.ОттеваЭ. Н.OttevaE. N.РаскинаТ. А.RaskinaT. A.РебровА. П.RebrovA. P.РумянцеваО. А.RumyantsevaO. A.СиталоА. В.SitaloA. V.СмирновА. В.SmirnovA. V.ЭрдесШ. Ф.ErdesSh. F.Казанский государственный медицинский университет, Минздрав России, КазаньРоссияKazan State Medical University, Ministry of Health of Russia; KazanRussian FederationНаучно-исследовательский институт ревматологии имени В.А. Насоновой, МоскваРоссияV.A. Nasonova Research Institute of Rheumatology, MoscowRussian FederationРоссийская медицинская академия постдипломного образования, Минздрав России, МоскваРоссияRussian Medical Academy of Postgraduate Education, Ministry of Health of Russia, MoscowRussian FederationМедицинский центр «Агат», ЕгорьевскРоссияAgat Medical Center, Egoryevsk, Moscow RegionRussian FederationОренбургский государственный медицинский университет, Минздра России, ОренбургРоссияOrenburg State Medical University, Ministry of Health of Russia, OrenburgRussian FederationСаратовский государственный медицинский университет имени В.И. Разумовского, Минздрав России, СаратовРоссияV.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia, SaratovRussian FederationТихоокеанский государственный медицинский университет, Минздрав России, ВладивостокРоссияPacific State Medical University, Ministry of Health of Russia, VladivostokRussian FederationВоронежская областная клиническая больница №1, ВоронежРоссияVoronezh Regional Clinical Hospital One, VoronezhRussian FederationЧелябинская областная клиническая больница, ЧелябинскРоссияChelyabinsk Regional Clinical Hospital, ChelyabinskRussian FederationИнститут подвздошных суставов (КПС) и/или позвоспективных контролируемых исследованиях [9, повышения квалификации специалистов здравоохранения, Минздрав Хабаровского края, ХабаровскРоссияInstitute for Advanced Training of Healthcare Specialists, Ministry of Health of the Khabarovsk Territory, KhabarovskRussian FederationКемеровская государственная медицинская академия, Минздрав России, КемеровоРоссияKemerovo State Medical Academy, Ministry of Health of Russia, KemerovoRussian FederationОбщество взаимопомощи при болезни Бехтерева, МоскваРоссияSociety of Mutual Assistance in Bechterew's Disease, MoscowRussian Federation201616092016541Sприложение 17579Copyright © Лапшина С.А., Дубинина Т.В., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Гайдукова И.З., Годзенко А.А., Дубиков А.А., Иванова О.Н., Коротаева Т.В., Несмеянова О.Б., Никишина И.П., Оттева Э.Н., Раскина Т.А., Ребров А.П., Румянцева О.А., Ситало А.В., Смирнов А.В., Эрдес Ш.Ф., 20162016Лапшина С.А., Дубинина Т.В., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Гайдукова И.З., Годзенко А.А., Дубиков А.А., Иванова О.Н., Коротаева Т.В., Несмеянова О.Б., Никишина И.П., Оттева Э.Н., Раскина Т.А., Ребров А.П., Румянцева О.А., Ситало А.В., Смирнов А.В., Эрдес Ш.Ф.Lapshina S.A., Dubinina T.V., Badokin V.V., Bochkova A.G., Bugrova O.V., Gaidukova I.Z., Godzenko A.A., Dubikov A.A., Ivanova O.N., Korotaeva T.V., Nesmeyanova O.B., Nikishina I.P., Otteva E.N., Raskina T.A., Rebrov A.P., Rumyantseva O.A., Sitalo A.V., Smirnov A.V., Erdes S.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2257

Представлен обзор рекомендаций по использованию ингибиторов фактора некроза опухоли α (иФНОα) у пациентов с аксиальным спондилоартритом (аксСпА),  включая анкилозирующий спондилит.  Приведены данные об эффективности иФНОα у пациентов с нерентгенологическим аксСпА. На основании международных и отечественных  рекомендаций сформулированы показания к назначению данной терапии,  критерии оценки  ее эффективности и безопасности.

The paper provides guidelines for the use of tumor necrosis factor-α  (TNF-α) inhibitors in the treatment of patients with axial spondyloarthritis  (axSpA), including ankylosing spondylitis. It gives data on the efficacy of TNF-α inhibitors in patients with non-radiographic axSpA. By using international and Russian guidelines, the authors lay down indications for this therapy and criteria for evaluation of its efficiency and safety.

аксиальный спондилоартританкилозирующий спондилитингибиторы фактора некроза опухоли αэффективностьбезопасностьaxial spondyloarthritisankylosing spondylitistumor necrosis factor-α (TNF-α) inhibitorsefficacysafetyReferencesНасонов ЕЛ, редактор. Ревматология: Клинические рекомендации. 2-е изд. Москва: ГЭОТАР-Медиа; 2010. 752 c. [Nasonov EL, editor. Revmatologiya: Klinicheskie rekomendatsii. [Rheumatology: Clinical guidelines]. 2nd ed. Moscow: GEOTAR-Media; 2010. 752 p.].Насонов ЕЛ, редактор. Ревматология: Клинические рекомендации. 2-е изд. Москва: ГЭОТАР-Медиа; 2010. 752 c. [Nasonov EL, editor. Revmatologiya: Klinicheskie rekomendatsii. [Rheumatology: Clinical guidelines]. 2nd ed. Moscow: GEOTAR-Media; 2010. 752 p.].Эрдес ШФ. Основные принципы терапии анкилозирующего спондилита (болезни Бехтерева). Научно-практическая ревматология. 2013;51(6):686-95 [Erdes ShF. The basic principles of treatment of ankylosing spondylitis (Bechterew’s disease). NauchnoPrakticheskaya Revmatologiya=Rheumatology Science and Practice. 2013;51(6):686-95 (In Russ.)]. doi: 10.14412/1995-4484-2013-686-95Эрдес ШФ. Основные принципы терапии анкилозирующего спондилита (болезни Бехтерева). Научно-практическая ревматология. 2013;51(6):686-95 [Erdes ShF. The basic principles of treatment of ankylosing spondylitis (Bechterew’s disease). NauchnoPrakticheskaya Revmatologiya=Rheumatology Science and Practice. 2013;51(6):686-95 (In Russ.)]. doi: 10.14412/1995-4484-2013-686-95Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71 Suppl 2:i2-45. doi: 10.1136/annrheumdis-2011-201036Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71 Suppl 2:i2-45. doi: 10.1136/annrheumdis-2011-201036Wang D, Ma L, Wu D. Efficacy of etanercept in ankylosing spondylitis hip lesions. Joint Bone Spine. 2011 Oct;78(5):531-2. doi: 10.1016/j.jbspin.2011.03.023Wang D, Ma L, Wu D. Efficacy of etanercept in ankylosing spondylitis hip lesions. Joint Bone Spine. 2011 Oct;78(5):531-2. doi: 10.1016/j.jbspin.2011.03.023Эрдес ШФ. Применение голимумаба при анкилозирующем спондилите. Научно-практическая ревматология. 2012;50(Прил. 3):11-6 [Erdes ShF. The use of golimumab in ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya=Rheumatology Science and Practice. 2012;50(Suppl. 3):11-6 (In Russ.)].Эрдес ШФ. Применение голимумаба при анкилозирующем спондилите. Научно-практическая ревматология. 2012;50(Прил. 3):11-6 [Erdes ShF. The use of golimumab in ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya=Rheumatology Science and Practice. 2012;50(Suppl. 3):11-6 (In Russ.)].Эрдес ШФ. Этанерцепт в терапии анкилозирующего спондилита. Научно-практическая ревматология. 2012;50(Прил. 4):28-34 [Erdes ShF. Etanercept in the treatment of ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya=Rheumatology Science and Practice. 2012;50(Suppl. 4): 28-34 (In Russ.)].Эрдес ШФ. Этанерцепт в терапии анкилозирующего спондилита. Научно-практическая ревматология. 2012;50(Прил. 4):28-34 [Erdes ShF. Etanercept in the treatment of ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya=Rheumatology Science and Practice. 2012;50(Suppl. 4): 28-34 (In Russ.)].Haroon N, Inman RD, Learch TJ, et al. The Impact of TNFinhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013 Oct;65(10):2645-54. doi: 10.1002/art.38070Haroon N, Inman RD, Learch TJ, et al. The Impact of TNFinhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013 Oct;65(10):2645-54. doi: 10.1002/art.38070Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000 Jun;59(6):428-33. doi: 10.1136/ard.59.6.428Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000 Jun;59(6):428-33. doi: 10.1136/ard.59.6.428Brandt J, Haibel H, Sieper J, et al. Treatment of patients with severe ankylosing spondylitis with infliximab – a one year follow up. Arthritis Rheum. 2001 Dec;44(12):2936-7. doi: 10.1002/1529-0131(200112)44:12<2936::AID-ART483>3.0.CO;2-MBrandt J, Haibel H, Sieper J, et al. Treatment of patients with severe ankylosing spondylitis with infliximab – a one year follow up. Arthritis Rheum. 2001 Dec;44(12):2936-7. doi: 10.1002/1529-0131(200112)44:12<2936::AID-ART483>3.0.CO;2-MKruithof E, van den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNF-α monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis. 2002 Mar;61(3):207-12. doi: 10.1136/ard.61.3.207Kruithof E, van den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNF-α monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis. 2002 Mar;61(3):207-12. doi: 10.1136/ard.61.3.207Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 2001 Sep;44(9):2112-7. doi: 10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-HMarzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 2001 Sep;44(9):2112-7. doi: 10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-HInman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008 Nov;58(11):3402-12. doi: 10.1002/art.23969Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008 Nov;58(11):3402-12. doi: 10.1002/art.23969Spadaro A, Scarno A, Carboni A, et al. Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis. Reumatismo. 2013 Jul 24;65(3):134-7. doi: 10.4081/reumatismo.2013.134Spadaro A, Scarno A, Carboni A, et al. Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis. Reumatismo. 2013 Jul 24;65(3):134-7. doi: 10.4081/reumatismo.2013.134Braun J, Pham T, Sieper J, et al; ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003 Sep;62(9):817-24. doi: 10.1136/ard.62.9.817Braun J, Pham T, Sieper J, et al; ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003 Sep;62(9):817-24. doi: 10.1136/ard.62.9.817Van der Heijde D, Sieper J, Maksymowych WP, et al, for the Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905-8. doi: 10.1136/ard.2011.151563Van der Heijde D, Sieper J, Maksymowych WP, et al, for the Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905-8. doi: 10.1136/ard.2011.151563Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014 Jan;73(1):6-16. doi: 10.1136/annrheumdis-2013-203419Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014 Jan;73(1):6-16. doi: 10.1136/annrheumdis-2013-203419Rudwaleit M, van der Heijde D, Landewe R, et al. The development of assessment of spondyloarthritis international society classiс cation criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777-83. doi: 10.1136/ard.2009.108233Rudwaleit M, van der Heijde D, Landewe R, et al. The development of assessment of spondyloarthritis international society classiс cation criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777-83. doi: 10.1136/ard.2009.108233Lukas C, Landewe R, Sieper J, et al. Development of an ASASendorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Assessment of SpondyloArthritis international Society. Ann Rheum Dis. 2009 Jan;68(1):18-24. doi: 10.1136/ard.2008.094870Lukas C, Landewe R, Sieper J, et al. Development of an ASASendorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Assessment of SpondyloArthritis international Society. Ann Rheum Dis. 2009 Jan;68(1):18-24. doi: 10.1136/ard.2008.094870Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015 Apr 18;4:CD005468. doi: 10.1002/14651858.CD005468.pub2Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015 Apr 18;4:CD005468. doi: 10.1002/14651858.CD005468.pub2Rudwaleit M, van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12:R117. doi: 10.1186/ar3054Rudwaleit M, van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12:R117. doi: 10.1186/ar3054Dougados M, Combe B, Braun J, et al. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis. 2010;69:1430-5. doi: 10.1136/ard.2009.121533Dougados M, Combe B, Braun J, et al. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis. 2010;69:1430-5. doi: 10.1136/ard.2009.121533Braun J, Baraliakos X, Hermann K-GA, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis. 2014 Jun;73(6):1107-13. doi: 10.1136/annrheumdis-2012-203075Braun J, Baraliakos X, Hermann K-GA, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis. 2014 Jun;73(6):1107-13. doi: 10.1136/annrheumdis-2012-203075Song IH, WeiІ A, Hermann KG, et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis. 2013;72(6);823-5. doi: 10.1136/annrheumdis-2012-202389Song IH, WeiІ A, Hermann KG, et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis. 2013;72(6);823-5. doi: 10.1136/annrheumdis-2012-202389Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis. 2011;70(4);590-6. doi: 10.1136/ard.2010.139667Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis. 2011;70(4);590-6. doi: 10.1136/ard.2010.139667Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014 Jan;73(1):101-7. doi: 10.1136/annrheumdis-2012-203201Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014 Jan;73(1):101-7. doi: 10.1136/annrheumdis-2012-203201Бочкова АГ, Румянцева OA, Дубинина ТВ и др. Первый опыт применения адалимумаба у больных анкилозирующим спондилитом: клиническое и МРТ-сопоставление результатов терапии. Научно-практическая ревматология. 2010;48(1):67-74 [Bochkova AG, Rumyantseva OA, Dubinina TV, et al. The first experience in using adalimumab in patients with ankylosing spondylitis: clinical and mricomparisons of the results of therapy. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2010;48(1):67-74 (In Russ.)]. doi: 10.14412/1995-4484-2010-1408.Бочкова АГ, Румянцева OA, Дубинина ТВ и др. Первый опыт применения адалимумаба у больных анкилозирующим спондилитом: клиническое и МРТ-сопоставление результатов терапии. Научно-практическая ревматология. 2010;48(1):67-74 [Bochkova AG, Rumyantseva OA, Dubinina TV, et al. The first experience in using adalimumab in patients with ankylosing spondylitis: clinical and mricomparisons of the results of therapy. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2010;48(1):67-74 (In Russ.)]. doi: 10.14412/1995-4484-2010-1408.Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70:6973-81. doi: 10.1136/ard.2010.147744Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70:6973-81. doi: 10.1136/ard.2010.147744Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis. 2013 Feb;5(1):45-54. doi: 10.1177/1759720X12468658Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis. 2013 Feb;5(1):45-54. doi: 10.1177/1759720X12468658Bennett N, McGonagle D, O'Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58(11):3413-8. doi: 10.1002/art.24024Bennett N, McGonagle D, O'Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58(11):3413-8. doi: 10.1002/art.24024Poddubnyy D, RudwaleitM. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011 Aug;70(8):1369-74. doi: 10.1136/ard.2010.145995Poddubnyy D, RudwaleitM. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011 Aug;70(8):1369-74. doi: 10.1136/ard.2010.145995Poddubnyy D, Sieper J. Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful? Curr Opin Rheumatol. 2012 Jul;24(4):363-9. doi: 10.1097/BOR.0b013e328352b7bdPoddubnyy D, Sieper J. Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful? Curr Opin Rheumatol. 2012 Jul;24(4):363-9. doi: 10.1097/BOR.0b013e328352b7bdЭрдес ШФ, Бочкова АГ, Дубинина ТВ и др. Ранняя диагностика анкилозирующего спондилита. Научно-практическая ревматология. 2013;51(4):365-7 [Erdes SF, Bochkova AG, Dubinina TV, et al. Early diagnosis of ankylosing spondylitis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(4):365-7 (In Russ.)]. doi: 10.14412/1995-4484-2013-1245Эрдес ШФ, Бочкова АГ, Дубинина ТВ и др. Ранняя диагностика анкилозирующего спондилита. Научно-практическая ревматология. 2013;51(4):365-7 [Erdes SF, Bochkova AG, Dubinina TV, et al. Early diagnosis of ankylosing spondylitis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(4):365-7 (In Russ.)]. doi: 10.14412/1995-4484-2013-1245Inman RD, Maksymowich WP for the CANDLE Study Group. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010;37:6. doi: 10.3899/jrheum.091042Inman RD, Maksymowich WP for the CANDLE Study Group. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010;37:6. doi: 10.3899/jrheum.091042Cantini F, Niccoli L, Cassara E, et al. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-upstudy. Biologics. 2013;7:1-6. doi: 10.2147/BTT.S31474Cantini F, Niccoli L, Cassara E, et al. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-upstudy. Biologics. 2013;7:1-6. doi: 10.2147/BTT.S31474Arends S, van der Veer E, Kamps FB, et al. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol. 2015 Mar-Apr;33(2):174-80.Arends S, van der Veer E, Kamps FB, et al. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol. 2015 Mar-Apr;33(2):174-80.Olivieri I, D'Angelo S, Padula A, et al. Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev. 2013 May;12(7):691-3. doi: 10.1016/j.autrev.2012.08.013Olivieri I, D'Angelo S, Padula A, et al. Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev. 2013 May;12(7):691-3. doi: 10.1016/j.autrev.2012.08.013Song IH, Haibel H, Poddubnyy D, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl. 78):S37-42.Song IH, Haibel H, Poddubnyy D, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl. 78):S37-42.Spadaro A, Punzi L, Marchesoni A, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford). Jun 2010;49(6):1107-11. doi: 10.1093/rheumatology/keq008Spadaro A, Punzi L, Marchesoni A, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford). Jun 2010;49(6):1107-11. doi: 10.1093/rheumatology/keq008Румянцева ОА, Бочкова АГ, Кузикянц КХ и др. Опыт длительной терапии инфликсимабом у больных анкилозирующим спондилитом. Научно-практическая ревматология. 2010;48(6):16-22 [Rumyantseva OA, Bochkova AG, Kuzikyants KK, et al. Experience with long-term infliximab therapy in patients with ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2010;48(6):16-22. (In Russ.)]. doi: 10.14412/1995-4484-2010-818Румянцева ОА, Бочкова АГ, Кузикянц КХ и др. Опыт длительной терапии инфликсимабом у больных анкилозирующим спондилитом. Научно-практическая ревматология. 2010;48(6):16-22 [Rumyantseva OA, Bochkova AG, Kuzikyants KK, et al. Experience with long-term infliximab therapy in patients with ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2010;48(6):16-22. (In Russ.)]. doi: 10.14412/1995-4484-2010-818Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. Clin Exp Rheumatol. 2013;31(Suppl. 78):S33-6.Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. Clin Exp Rheumatol. 2013;31(Suppl. 78):S33-6.Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis. 2012;71(7);1212-5. doi: 10.1136/annrheumdis-2011-201010Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis. 2012;71(7);1212-5. doi: 10.1136/annrheumdis-2011-201010Wu D, Guo YY, Xu NN, et al. Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord. 2015 Feb 10;16:19. doi: 10.1186/s12891-015-0489-2Wu D, Guo YY, Xu NN, et al. Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord. 2015 Feb 10;16:19. doi: 10.1186/s12891-015-0489-2Эрдес ШФ. Эффективность адалимумаба при увеитах у больных анкилозирующим спондилитом. Современная ревматология. 2012;6(1):65-8 [Erdes SF. Efficacy of adalimumab in uveitis in patients with ankylosing spondylitis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2012;6(1):65-8. (In Russ.)]. doi: 10.14412/1996-7012-2012-719Эрдес ШФ. Эффективность адалимумаба при увеитах у больных анкилозирующим спондилитом. Современная ревматология. 2012;6(1):65-8 [Erdes SF. Efficacy of adalimumab in uveitis in patients with ankylosing spondylitis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2012;6(1):65-8. (In Russ.)]. doi: 10.14412/1996-7012-2012-719Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of AS. Ann Rheum Dis. 2011;70:896-904. doi: 10.1136/ard.2011.151027Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of AS. Ann Rheum Dis. 2011;70:896-904. doi: 10.1136/ard.2011.151027Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):82-9. doi: 10.1007/s12016-009-8140-3Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):82-9. doi: 10.1007/s12016-009-8140-3Arends S, Lebbink HR, Spoorenberg A, et al. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2010 Sep-Oct;28(5):661-8.Arends S, Lebbink HR, Spoorenberg A, et al. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2010 Sep-Oct;28(5):661-8.Plasencia C, Pascual-Salcedo D, Nuno L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012 Dec;71(12):1955-60. doi: 10.1136/annrheumdis-2011-200828Plasencia C, Pascual-Salcedo D, Nuno L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012 Dec;71(12):1955-60. doi: 10.1136/annrheumdis-2011-200828Murdaca G, Spano F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016 Jan;15(1):43-52. doi: 10.1517/14740338.2016.1112375.Murdaca G, Spano F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016 Jan;15(1):43-52. doi: 10.1517/14740338.2016.1112375.

The authors declare that there are no conflicts of interest present.